Exelixis Provides Update On Phase 3 CONTACT-01 Trial Evaluating Cabozantinib In Combination With Atezolizumab In Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With Immunotherapy And Chemotherapy
Exelixis, Inc. (NASDAQ:EXEL) today announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating cabozantinib (CABOMETYX®)
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization For Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine In Children Under 5 Years
Bivalent vaccine authorized as third 3-µg dose in the three-dose primary series
Consistent COVID-19 hospitalization rates in this age group coupled with an overall surge in respiratory illnesses among children
Oncolytics Biotech’s Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating The Anti-Cancer Activity Of Pelareorep-Paclitaxel Combination Therapy In HR+/HER2- Metastatic Breast Cancer At SABCS
Thirteen of fourteen (93%) evaluable patients achieved disease control, with twelve (86%) showing tumor shrinkage
SAN DIEGO and CALGARY, AB, Dec. 8, 2022 /CNW/ -- Oncolytics
Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared In The U.S.; Shares Spike Higher
Dexcom G7 is now cleared in the U.S. for people with all Types of diabetes ages two years and older, giving more people than ever access to a powerfully simple diabetes management solution
With an overall MARD
Better Therapeutics Completes Exploratory Trial For Fatty Liver Disease And Announces Topline Results; Co. Reports ‘Study Conducted with Arizona Liver Health Met Primary Endpoint’
Study Conducted with Arizona Liver Health Met Primary Endpoint and Established Proof-of-Concept for Prescription Digital Therapy Platform to Improve Disease Biomarkers in NAFLD and NASH Patients
Company Intends to Apply
Relmada Therapeutics Says RELIANCE Trial For REL-1017 Did Not Meet Primary Endpoint
Company to Host Conference Call Today, December 7, 2022, at 5:00 PM ET
CORAL GABLES, Fla., Dec. 7, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company
Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability With CDK 4/6 Inhibitor Palbociclib In Phase 1b Dose Escalation Study
OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- breast cancer, with no dose-limiting toxicities, and no observed drug-drug interaction
No induced metabolism of palbociclib
Watching Sutro Biopharma; Traders Circulate FDA Orphan Drug Designation For ‘Treatment of pediatric acute myeloid leukemia’
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=915722